Hornig B, Arakawa N, Drexler H
Abteilung Kardiologie, Medizinische Hochschule Hannover, Germany.
Eur Heart J. 1998 Jul;19 Suppl G:G48-53.
The endothelium controls vascular smooth muscle tone by secreting relaxing and contracting factors. There is a constant release of endothelium-derived relaxing factors(s) (EDRF) under basal conditions. In addition, the endothelium can increase the release of EDRF in response to humoral stimulation by vasoactive substances such as acetylcholine or bradykinin. Under physiological conditions the most important stimulus to the release of EDRF is an increase in blood flow, leading to increased shear stress on endothelial cells. Recent experimental studies have raised the possibility that bradykinin plays an important role in the regulation of vascular tone at rest and during flow-stimulated conditions. Bradykinin is a very potent vasodilator that exerts its vasodilatory actions by causing endothelial release of nitric oxide, prostacyclin and/or endothelium-derived hyperpolarizing factor. Recent studies in humans have demonstrated that bradykinin contributes to the regulation of coronary vascular tone under resting and flow-stimulated conditions. This mechanism has been shown to be important in humans in both peripheral and coronary arteries. Angiotensin-converting enzyme (ACE) inhibitors not only decrease angiotensin II but also increase bradykinin levels, since ACE is identical to kininase II, which degrades bradykinin. The beneficial vascular effects of ACE inhibitors may therefore be related to increased availability of bradykinin. Indeed, we have recently shown that ACE inhibition improves flow-dependent, endothelium-mediated vasodilation and that this beneficial effect is bradykinin-dependent. Our preliminary data also indicate that ACE inhibition improves endothelium-mediated vasodilation in patients with heart failure and coronary artery disease due to an enhanced availability of nitric oxide. These findings suggest that the beneficial vascular effects of ACE inhibition in heart failure may be due in part to improved endothelial function.
内皮细胞通过分泌舒张和收缩因子来控制血管平滑肌张力。在基础条件下,内皮源性舒张因子(EDRF)会持续释放。此外,内皮细胞可响应血管活性物质如乙酰胆碱或缓激肽的体液刺激而增加EDRF的释放。在生理条件下,EDRF释放的最重要刺激因素是血流增加,导致内皮细胞上的剪切应力增加。最近的实验研究提出了缓激肽在静息和血流刺激条件下血管张力调节中起重要作用的可能性。缓激肽是一种非常强效的血管舒张剂,通过促使内皮细胞释放一氧化氮、前列环素和/或内皮源性超极化因子来发挥其血管舒张作用。最近在人体进行的研究表明,缓激肽在静息和血流刺激条件下有助于冠状动脉血管张力的调节。这一机制在人体的外周动脉和冠状动脉中均已证明很重要。血管紧张素转换酶(ACE)抑制剂不仅能降低血管紧张素II水平,还能提高缓激肽水平,因为ACE与降解缓激肽的激肽酶II是同一种酶。因此,ACE抑制剂有益的血管效应可能与缓激肽可用性增加有关。事实上,我们最近表明,抑制ACE可改善血流依赖性、内皮介导的血管舒张,且这种有益作用依赖于缓激肽。我们的初步数据还表明,抑制ACE可改善心力衰竭和冠状动脉疾病患者内皮介导的血管舒张,原因是一氧化氮的可用性增加。这些发现提示,ACE抑制在心力衰竭中有益的血管效应可能部分归因于内皮功能的改善。